Patents Assigned to AstraZeneca
  • Nicotinic acetylcholine receptor ligands
    Publication number: 20070191422
    Abstract: Compounds of formula (I), wherein D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Application
    Filed: December 20, 2004
    Publication date: August 16, 2007
    Applicant: AstraZeneca AB
    Inventors: Glen Ernst, Robert Jacobs, Eifion Phillips
  • Automatically Operable Safety Shield System for Syringes
    Publication number: 20070191783
    Abstract: An automatically operable safety shield system for use with a syringe that comprises an inner holder in which said syringe may be inserted and an outer shield mounted outwards from the inner holder axially movable between retracted and extended positions in which a spring positioned between said inner holder and said outer shield urging the outer shield to its extended position and the inner holder having at least one first opening, distally thereto, at least one first indentation, and the outer shield having at least one first stop member engageable with the opening when the outer shield is in the retracted position engageable with the first indentation when the outer shield is in the extended position and the outer shield may be released from its retracted position by action of a trigger positioned within the inner holder or by protrusion on the syringe plunger.
    Type: Application
    Filed: April 26, 2007
    Publication date: August 16, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Derek Shaw, Brian Law
  • 9-Substituted 8-oxoadenine compound
    Publication number: 20070190071
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 16, 2007
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., AstraZeneca Aktiebolag
    Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
  • Selective estrogen receptor-? ligands
    Patent number: 7256201
    Abstract: The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-? ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 14, 2007
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, Cathy Dantzman
  • Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor ?(PPAR)
    Patent number: 7256307
    Abstract: The present invention provides the S enantiomer of a compound of formula (I); wherein R1 represents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: August 14, 2007
    Assignee: AstraZeneca AB
    Inventors: Eva-lotte Alstermark Lindstedt, Anna Christina Olsson, Lanna Li
  • 3-aminoalkyl-2-aryl-indole derivatives and their use as GnRH antagonists
    Patent number: 7256188
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: August 14, 2007
    Assignee: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • Pharmaceutical Compositions
    Publication number: 20070185080
    Abstract: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.
    Type: Application
    Filed: November 17, 2006
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Hans Eriksson, Martin Brecher, Rohini Chitra, Joan Shaw, Marten Vagero, Ellis Wilson
  • Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
    Publication number: 20070185100
    Abstract: The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X5, X6, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicant: AstraZeneca AB
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Annika Kers, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, David Wensbo, Tao Xin, Bjorn Holm
  • Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
    Publication number: 20070185095
    Abstract: The present invention is directed to compounds of formula: (I); wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds for treating gastrointestinal disorders.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Martin Johansson, David Wensbo, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tomislav Stefanac, Abdelmalik Slassi, Donald McLeod, Tao Xin
  • Therapeutic agents I
    Publication number: 20070185079
    Abstract: Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.
    Type: Application
    Filed: January 5, 2005
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Emma Evertsson, Tord Inghardt, Jan Lindberg, Anna Linusson, Fabrizio Giordanetto
  • Chroman compounds
    Publication number: 20070185107
    Abstract: Compounds according to Formula (I): wherein R1, R2, R3, and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: November 3, 2006
    Publication date: August 9, 2007
    Applicant: AstraZeneca AB
    Inventors: Peter Bernstein, Daniel Hill, David Nugiel, Edward Pierson, Ashokkumar Shenvi, Robert Jacobs
  • Therapeutic agents II
    Publication number: 20070185119
    Abstract: Compounds of Formula (I) as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 5, 2005
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Emma Evertsson, Tord Inghardt, Jan Lindberg, Anna Linusson
  • New compounds
    Publication number: 20070185179
    Abstract: The present invention relates to new compounds of formula I, where R1 and R2 are independently halo or C1-3haloalkyl, X is ethenyl or ethynyl, or a salt thereof.
    Type: Application
    Filed: February 5, 2007
    Publication date: August 9, 2007
    Applicant: AstraZeneca AB
    Inventors: Carmen Leugn, Miroslaw Tomaszewski, Simon Woo
  • Derivatives of thienopyrrole as gnrh antagonists
    Publication number: 20070185185
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I) wherein: R1, R2, R3, R4 are as defined in the specification, which compounds are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventors: David Andrews, Zbigniew Matusiak
  • Imidazol derivatives of piperidine as histamine antagonists
    Publication number: 20070185163
    Abstract: Piperidine compounds according to Formula I wherein R1, m, X, n, p, q, Y, Z and Ar are acs defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy and in the preparation of medicaments.
    Type: Application
    Filed: July 19, 2004
    Publication date: August 9, 2007
    Applicant: AstraZeneca AB
    Inventors: Fraser Hunt, Peter Hamley
  • Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists
    Publication number: 20070185106
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of formula (I) wherein: R1, R2, R3, R4 M, and R5 are as defined in the specification, as inter alia, gonadotrophin releasing hormone antagonists. Novel compounds of formula (I) are also claimed. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventor: Craig Harris
  • Post harvest treatment of crops
    Publication number: 20070184080
    Abstract: Novel processes and combinations of matter for treating fresh produce to seal fresh-cut stems to reduce moisture loss and inhibit fungus, mold, rot and insect infestation at the site where the produce was separated from the plant stalk. Natural and commercially produced waxes are modified with elastomers to render efficacy for sealing produce at ambient and refrigerated temperatures, thus reducing moisture loss, reducing oxygen beneath the wax, and thus preventing infestation. The result is reduced loss of fresh produce due to moisture loss and infestation; and a safe, economical, and environmentally superior alternative to fungicides and biocides and brand enhancement opportunities in the general marketplace.
    Type: Application
    Filed: October 7, 2003
    Publication date: August 9, 2007
    Applicant: AstraZeneca UK Ltd
    Inventor: Vernon KEATING
  • 2-(Arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
    Publication number: 20070185127
    Abstract: Compounds of the following formula (I) wherein R1 R2, n, A1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are neurokinin 1 (NK1) receptor antagonist and/or serotonin reuptake inhibitors, with medical indications for depression and other disorders.
    Type: Application
    Filed: April 6, 2005
    Publication date: August 9, 2007
    Applicant: ASTRAZENECA AB
    Inventor: Cathy Dantzman
  • Pyrazole derivatives as GnRH inhibitors
    Patent number: 7253290
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R5, R6, R6a, R7, R8, A, B and M are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: August 7, 2007
    Assignee: AstraZeneca AB
    Inventors: Thomas Geoffrey Bird, Mickael Louis Pierre Maudet
  • 4-Substituted quinolines as antitumor agents
    Patent number: 7253184
    Abstract: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the treatment of solid tumour disease.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: August 7, 2007
    Assignee: AstraZeneca AB
    Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson